Understand the source comparison
Peptides for Liver Health: Protocol Comparison
Thymalin (thymic peptide) T-cell modulation; cytokine suppression 10mg IM twice weekly × 10 weeks St. Petersburg Institute: 33% ALT reduction, 41% CRP reduction 8–10 weeks Strongest human trial data; best for inflammatory liver disease Epithalamic peptides Cir
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymalin (thymic peptide)
- T-cell modulation; cytokine suppression
- 10mg IM twice weekly × 10 weeks
- St. Petersburg Institute: 33% ALT reduction, 41% CRP reduction
- 8–10 weeks
- Strongest human trial data; best for inflammatory liver disease
- Epithalamic peptides
- Circadian regulation; antioxidant gene upregulation
- 5mg SC twice weekly × 12 weeks
- Animal models: 28–34% oxidative marker reduction
- 10–12 weeks
- Indirect hepatoprotection; synergistic with direct interventions
- Liver bioregulatory peptides
- Hepatocyte transcription factor binding
- 5–10mg SC twice weekly × 8 weeks
- Moscow State: 41% fibrosis reduction (animal model)
- 6–8 weeks
- Most targeted; limited human data; promising preclinical results
- NAC (antioxidant, non-peptide)
- Glutathione precursor; ROS neutralization
- 600–1200mg oral daily
- Meta-analysis: modest enzyme reduction; inconsistent across studies
- 12–16 weeks
- Reactive mechanism; works downstream; safe and accessible